Preclinical imaging developer MILabs has installed its new PET/SPECT/CT/MRI platform at the In Vivo Cellular and Molecular Imaging (ICMI) Lab at the University Brussels (VUB) Belgium.
The platform combines PET/SPECT functional imaging capabilities with anatomical imaging from an integrated x-ray CT subsystem and/or a compact, cryogen-free, 1.5-tesla MRI unit, MILabs said.
The preclinical imaging research at ICMI has been the basis for several clinical trials using radiolabeled nanobodies.
